Shun Q. Lu
241 West Huaihai Road
Huaihai, 200030, China
Huaihai, 200030, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 473 publications
Is There Still Room for Monotherapy in EGFR-Mutated Non-Small Cell Lung Cancer?
Journal: JAMA
Published: August 10, 2026
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial.
Journal: JAMA surgery
Published: July 15, 2026
Author Correction: A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.
Journal: Nature microbiology
Published: June 16, 2026
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.
Journal: Future oncology (London, England)
Published: June 03, 2026
FAK co-inhibition in KRASG12C-mutated non-small-cell lung cancer.
Journal: The Lancet. Respiratory medicine
Published: May 17, 2026
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.
Journal: Future oncology (London, England)
Published: April 27, 2026
Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 24, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
Journal: Lancet (London, England)
Published: April 23, 2026
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 03, 2026
International Consensus on Severe Lung Cancer-The Second Edition.
Journal: Translational lung cancer research
Published: March 21, 2026
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 06, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 26, 2026
Last Updated: 09/26/2026